Bone loss and fractures in patients on androgen deprivation therapy

Juan Morote Robles, Jacques Planas Morin

Research output: Contribution to journalArticleResearchpeer-review


Therapy based on androgenic deprivation is one of the standard treatments that many prostate cancer patients receive. Moreover, its use is increasing owing to a clear expansion of the indications for this therapy in patients with localised cancer. Despite classically being considered to be well tolerated, androgenic deprivation has adverse effects. Of these, the loss of mineral bone mass is particularly notable and can lead to osteoporosis, as well as an increased risk of bone fracture. Some fractures, such as hip fractures, may have serious consequences. Useful procedures such as bone densitometry can aid in the diagnosis of these conditions. Once diagnosed, decreases in mineral bone mass can be managed by dietary recommendations, general changes in lifestyle or medication. Following the applicable recommendations, urologists must carefully monitor the bone health of prostate cancer patients subjected to androgenic deprivation to obtain an early diagnosis and apply the appropriate general and/or therapeutic measures if necessary. © TOUCH BRIEFINGS 2011.
Original languageEnglish
Pages (from-to)98-102
JournalEuropean Urological Review
Issue number2
Publication statusPublished - 1 Dec 2011


  • Androgen deprivation therapy
  • Bisphosphonates
  • Bone fracture
  • Bone mass loss
  • Calcium intake
  • Osteoclast
  • Osteoporosis
  • Prostate cancer
  • Receptor activator of nuclear factor-κB to ligand


Dive into the research topics of 'Bone loss and fractures in patients on androgen deprivation therapy'. Together they form a unique fingerprint.

Cite this